RE:RE:ONCY pelareorep + PARP inhibitors = enhanced sensitizationNumerous clinical trials are ongoing to develop next-generation PARPi and validate the use of combination therapies, particularly the potential synergistic effect of PARPi with ICIs.
Additional studies are necessary to investigate potential PARPi combinations in groups of patients who have clinically unmet anticancer needs, including patients who do not respond well to established PARPi/ICI monotherapies.
Biomarkers are critical in identifying optimal patient populations.